Alumis Stock Valuation Check: Balancing Momentum and Risks
ByAinvest
Saturday, Feb 7, 2026 3:21 pm ET1min read
ALMS--
Alumis (ALMS) stock price has surged 6.9% in the past week, 46% in the past month, and 361.9% in the past year. The company trades at a price-to-book ratio of 8.5x, which is considered rich compared to the US Pharmaceuticals industry. Despite being unprofitable and carrying a high return on equity, Alumis' revenue is forecast to grow 58.1% per year, which may justify the premium price tag. However, the stock carries significant risks, including ongoing losses and reliance on clinical progress for its pipeline.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet